

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
May 20, 2014**

The quarterly meeting of the ODM DUR Board was called to order at 12:04 PM in Room West B and C, 31st Floor Riffe Center, 77 S. High Street, Columbus, Ohio. Thomas Gretter, MD, presided. The following Board members were present:

David Brookover, RPh, Chair
Michael Farrell, MD
Thomas Gretter, MD
Robert Kubasak, RPh
J. Layne Moore, MD
Donald Sullivan, RPh, PhD

Also present were Jill Griffith, RPh, DUR Director; Pam Heaton, RPh, PhD from the University Of Cincinnati College Of Pharmacy; and Margaret Scott, RPh, DUR Administrator. Approximately 12 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The February 25th, 2014, DUR Board minutes were approved. (1st M. Farrell, 2nd D. Brookover).

Health Plan Policy:

M. Scott announced that the Preferred Drug List (PDL) is under construction and contains no new drug categories this year. A Request for Information (RFI) was released to help inform the formal Request for Proposal (RFP) document regarding the upcoming Prescription Benefit Manager (PBM) contract. The cost of dispensing survey RFP was also released. M. Scott announced the pharmacist position has been filled and the new pharmacist will start next month. Medicaid will also put into place a buprenorphine 16 mg per day limit (unless prescription written by an addictionologist or psychiatrist) as per the Governors' Cabinet Opiate Action Team (GCOAT) recommendations. Preventive doses of naloxone will be covered for high risk patients. High risk patients are defined as those in addiction treatment; those receiving methadone; those with known history of drug abuse; and those with respiratory disease receiving concurrent narcotics and benzodiazepines.

DUR Committee Report:

J. Griffith announced that the March DUR committee reviewed Morphine Equivalent Dose (MED) reports and heard a synopsis of the American Drug Utilization Review Symposium attended by J Griffith in February 2014. The April DUR Committee reviewed reports regarding: the number of patients on concurrent long-acting stimulants and sedatives; morphine equivalent doses (MED); and patients on concurrent benzodiazepines and narcotics. Intervention # 4007 Excessive Rescue Inhaler Use and Intervention # 4011 Duplicate Long-Acting Narcotics were also mailed in April. The May DUR Committee reviewed the profiles of 465 diabetic patients on short-acting (presumably prandial dosed) insulin concurrently with sulfonylureas or glinides. The Board reviewed and approved the letter to prescribers about the diabetic patients and reviewed results so far from previous mailings.

Unfinished Business:

M. Scott reviewed reports on antipsychotic use in long-term care and psychotropic use in children. The third quarter DUR Board meeting will be held on September 16th, 2014. The fourth quarter meeting will be held on November 18th 2014, (rooms to be determined). M. Scott announced that Ohio is hosting the American Medicaid Pharmacy Administrators Association (AMPAA) meeting in Cleveland August 24th through the 27th.

Adjournment:

T. Gretter adjourned the meeting at 12:36 PM

Respectfully submitted:

Jill RK Griffith BS, PharmD, DUR Program Director